MTOR and autoimmune polyendocrinopathy: Furthermore, as concomitant APS occurs in approximately one third of SLE patients and the mTOR pathway is involved in the vascular lesions related to APS, sirolimus may be of high importance regarding future studies of vascular disease in SLE (Canaud et al., 2014).